Charles University

First Faculty of Medicine

Summary of the doctoral thesis

UNIVERZITA KARLOVA
1. lékařská fakulta

The modification of gut microbiota composition by dietary intervention: the effect of plant-based and western-type diet

Ing. Nikola Ďásková

Prague, 2023

Appendix no. 1

Doctoral Study Programmes
in Biomedicine

*Charles University and Institute for Clinical
and Experimental Medicine*

Study Program: Biochemistry and Pathobiochemistry

Chairman of the Board: prof. MUDr. Zdeněk Kleibl, Ph.D.

Supervising department: Institut Klinické a Experimentální Medicíny, Praha

Supervisor: doc. RNDr. Monika Cahová, Ph.D.

The doctoral thesis will be available for public viewing in printed form at least five working days before the defense at the Department for Science and International Relations of the Dean's Office of the First Faculty of Medicine.

Appendix no. 1

CONTENTS

ABSTRACT

This thesis explores the relationship between diet, gut microbiota, and metabolic health, with a particular focus on their association with non-communicable metabolic diseases (NCDs) such as obesity and type 2 diabetes (T2D).

The aim of the first study is to assess compositional and metabolic differences in gut microbiota between healthy lean long-term vegans and omnivores. The study reveals that while the gut microbiota composition is not significantly different between the two groups, there are significant differences in the fecal, serum and urinary metabolome. These differences may be attributed to the different availability of substrates in the diet, as the vegan diet is associated with a shift from a proteolytic to a saccharolytic fermentation program. Our results support the hypothesis of both resilience and metabolic flexibility of the adult gut microbiota.

In addition to taxonomic analyses, this dissertation also includes metabolomics to evaluate the functional manifestations of the gut microbiota. We introduce a novel method to assess the ability of the gut microbiota to produce beneficial metabolites with a specific focus on butyrate synthesis using qPCR quantification of bacterial butyryl-CoA:acetate CoA-transferase. *In silico*, we identified bacteria among the human gut microbiota that possess the *but* gene, designed and validated six sets of degenerate primers covering all selected bacteria and developed a method to normalize gene abundance in human fecal DNA. We validated this method in subjects with opposite dietary habits and metabolic phenotypes - lean vegans (VG) and healthy obese omnivores (OB) - with known fecal microbiota and metabolome composition.

Furthermore, the effects of inulin treatment on glucose homeostasis in pre/diabetic patients were investigated. A three-month intervention with inulin under clinical trial conditions was associated with an overall improvement in glycemic indices, although the response was highly variable, with a shift in microbial composition towards a more favorable profile and an increase in serum butyric and propionic acid concentrations. Using multi-omics analysis, we identified biomarkers that predict treatment success. If further validated, these predictors could improve the estimation of outcomes of inulin interventions and contribute to personalized dietary management in early-stage diabetes.

Finally, the fourth study investigates the therapeutic potential of fecal microbial transfer (FMT) using vegan microbiota to treat non-infectious diseases. It uses a humanized mouse model to examine the effect of a Western-type diet (WD) and inulin supplementation on obesity, hepatic

steatosis, and glucose metabolism. We found that vegan microbiota alone did not protect against the adverse effects of WD and inulin supplementation reversed steatosis and normalized glucose metabolism. This phenomenon was related to a change in microbiota composition and an increase in saccharolytic fermentation at the expense of proteolytic fermentation. Our results highlighted that the success of fecal microbiota transfer in the treatment of metabolic noninfectious diseases depends not only on the microbiota transfer itself but also on subsequent dietary interventions involving inulin or other fiber and/or dietary changes.

This dissertation provides some new insights into the relationship between diet and the gut microbiome, particularly in relation to the therapeutic potential of targeted manipulation of the gut microbiota in the treatment of obesity and T2D. The study highlights the importance of dietary interventions, such as inulin or fiber supplementation, and emphasizes personalized dietary approaches to modify gut microbiota and improve metabolic health.

Key words:

Gut microbiome, metabolome, metabolic diseases, vegan diet, western type diet, animal models, type 2 diabetes, OMICS data

ABSTRAKT V ČEŠTINĚ

Tato dizertační práce zkoumá vztah mezi stravou, střevní mikrobiotou a metabolickým zdravím. Konkrétně se zaměřuje na vztah mezi složením střevní mikrobioty a nepřenosnými metabolickými chorobami, jako je obezita a diabetes 2. typu (T2D).

Cílem první studie je posoudit rozdíly ve složení a metabolismu střevní mikrobioty mezi zdravými štíhlými dlouhodobými vegany a omnivory. Studie ukazuje, že zatímco složení střevní mikrobioty se mezi oběma skupinami významně neliší, jsou zde významné rozdíly ve fekálním, sérovém a močovém metabolomu. Tyto rozdíly lze přičíst odlišné dostupnosti substrátů ve stravě, protože veganská strava je spojena s přechodem od proteolytického k sacharolytickému fermentačnímu programu. Naše výsledky podporují hypotézu o odolnosti i metabolické flexibilitě střevní mikrobioty u dospělých jedinců.

Kromě taxonomických analýz zahrnuje tato disertační práce také metabolomiku pro vyhodnocení funkčních projevů střevní mikrobioty. Zavádíme novou metodu hodnocení schopnosti střevní mikrobioty produkovat prospěšné metabolity se specifickým zaměřením na syntézu butyrátu pomocí qPCR kvantifikace bakteriální butyryl-CoA:acetát CoA-transferázy. In silico jsme identifikovali lidské střevní bakterie, které jsou vybaveny but genem, navrhli jsme a ověřili šest sad degenerovaných primerů pokrývajících všechny vybrané bakterie a vyvinuli metodu normalizace množství tohoto genu v lidské fekální DNA. Tuto metodu jsme ověřili u osob s opačnými stravovacími návyky a metabolickými fenotypy – u štíhlých veganů (VG) a zdravých obézních omnivorů (OB) – se známým složením fekální mikrobioty a metabolomu.

Dále jsme zkoumali účinky léčby inulinem na homeostázu glukózy u pre/diabetiků. Byla provedena klinická studie zahrnující tříměsíční inulinovou intervenci, která byla asociována s celkovým zlepšením glykemických parametrů, ačkoli individuální odpověď byla velmi variabilní, s posunem mikrobiálního složení směrem k příznivějšímu profilu a se zvýšením sérových koncentrací kyseliny máselné a propionové. Pomocí multi-omické analýzy jsme identifikovali biomarkery, které predikují úspěch léčby. Pokud budou tyto prediktory dále validovány, mohly by zlepšit odhad výsledků inulinových intervencí a přispět k personalizovanému dietnímu managementu v časném stadiu diabetu.

A konečně čtvrtá studie zkoumá terapeutický potenciál fekálního mikrobiálního transferu (FMT) s využitím veganské mikrobioty k léčbě nepřenosných metabolických onemocnění. Pomocí humanizovaného myšího modelu jsme sledovali vliv diety západního typu (WD) a podávání

inulinu na obezitu, jaterní steatózu a metabolismus glukózy. Zjistili jsme, že samotná veganská mikrobiota nechrání před nepříznivými účinky WD, ale naopak přídavek inulinu zvrátil steatózu a normalizoval metabolismus glukózy. Tento jev souvisel se změnou složení mikrobioty a zvýšením sacharolytické fermentace na úkor proteolytické fermentace. Naše výsledky zdůraznily, že úspěšnost přenosu fekální mikrobioty při léčbě metabolických onemocnění závisí nejen na samotném přenosu mikrobioty, ale také na následných dietních intervencích zahrnujících inulin nebo jinou vlákninu a/nebo změny stravy.

Tato disertační práce přináší některé nové poznatky o souvislostech mezi stravou a střevním mikrobiomem, zejména ve vztahu k terapeutickému potenciálu cílené manipulace se střevní mikrobiotou při léčbě obezity a T2D. Studie poukazuje na význam dietních intervencí, jako je suplementace vlákninou, a zdůrazňuje personalizované dietní přístupy k úpravě střevní mikrobioty a zlepšení metabolického zdraví.

Klíčová slova:

Střevní mikrobiom, střevní a sérový metabolom, metabolické poruchy, veganská dieta, dieta západního typu, zvířecí modely, diabetes druhého typu, OMICS data

1 INTRODUCTION

1.1 General preface

During my postgraduate studies, I focused on the relationship between microbial composition and some non-communicable metabolic diseases, particularly obesity and T2D. In our research, we did not limit ourselves to describing the taxonomic composition of the microbiota but also analyzed its functional manifestations through fecal metabolome analysis. We attempted to place the obtained results in the broader context of the interaction between the microbiome and the host organism by analyzing serum and urine metabolomes as well as health status indices and nutritional parameters. Furthermore, we described the microbiome and metabolome of vegan populations, which, according to numerous epidemiological studies, are metabolically healthier than the general omnivorous population. We were interested in whether the vegan diet affects the composition of the microbiome and metabolome and whether any favorable effects of this diet could be explained by their potential changes.

Targeted modulation of the gut microbiota is discussed as a potentially promising therapeutic strategy for diseases in which the pathophysiology of gut dysbiosis plays a role. However, the wider use of this approach is confronted with a lack of knowledge about the functioning of a system as complex as the gut microbiome and its interaction with the environment and the host. My work has addressed this issue both in humans (clinical intervention trial) and in an experimental study conducted in ex-germ-free (GF) mice. In the intervention study, we tested the hypothesis that the success of an inulin (dietary fiber) intervention to improve insulin sensitivity in T2D patients is variable and depends, at least in part, on the composition of the microbiome. In line with the hypothesis, we observed significant inter-individual differences in response to administered fiber and attempted to identify specific markers that would predict the success of this therapy. In the experimental study, we explored the potential use of vegan microbiota transfer in treating diet-induced obesity and insulin resistance.

1.2 The importance of gut microbiota and integration with other data types

A microbiota is a community of microorganisms living in a particular environment and refers to their taxonomy (each microorganism belongs to a set of taxonomic classification units from kingdom to species or even strains), which serves as an organizational tool (Parks et al., 2018). The broader and more recent term microbiome encompasses the set of all microorganisms (bacteria, archaea, lower and higher eukaryotes and viruses) inhabiting a particular environment

and their genomes and surrounding environmental conditions (Marchesi & Ravel, 2015) and was first defined and highly emphasized by professor and Nobel laureate Joshua Lederberg (Lederberg & McCray, 2001).

In the past few decades, research on the microbiome has been developing at a tremendous pace. The concept of the so-called "holobiont" was introduced in 1991 by evolutionary theorist and biologist Lynn Margulis and her graduate student René Fester (Margulis & Fester, 1991), although the concept itself has existed in nature since the first symbiosis, which is considered an essential part of evolution and the basis of the first eukaryotic cell, based on a theory proposed by Lynn Margulis in 1967 (Margulis, 1967) and widely accepted by scientists today. Currently, a holobiont is described as an organism consisting of a host and many microorganisms living in close association with the host (Bordenstein & Theis, 2015) (Simon et al., 2019). It is noteworthy that, based on currently available data, the number of bacterial cells present in the average human being is approximately the same order as the number of human cells, although it has been assumed that microbial cells outnumbered human cells (Sender et al., 2016b). Based on the estimates by Sender et al., the number of human cells in the 70 kg "reference" adult human is $3 \cdot 10^{13}$ with the major contributors being red blood cells, platelets, bone marrow cells, lymphocytes and endothelial cells (Sender et al., 2016a) (Sender et al., 2016b). The estimated number of bacterial cells in the same "reference" human is $3.9 \cdot 10^{13}$ (Sender et al., 2016a), but this number does not consider other types of microbes such as viruses and phages (Gilbert et al., 2018).

For a long time, the inner body was considered nearly sterile and any presence of microorganisms was considered as the consequence of "breaking the defense systems" and "wrong". Now, increasing evidence shows that almost every part of our body is populated by microbes. The abundance of microbes across human niches varies according to the chemical and physical aspects of each site or organ such as pH, concentration of oxygen, availability of nutrients, temperature, and presence of antimicrobial compounds or mucus (De Vos et al., 2022) (Milani et al., 2017). The human gut microbiome is currently attracting a great deal of scientific attention. The gastrointestinal tract (GIT) is home to complex and diversified microbial communities that influence many processes in our body. These communities vary greatly throughout the digestive tract due to the different physical and biochemical conditions in each part of the tract.

A typical aspect of the human gut microbiota is its interindividual variability, which is strongly related to environmental factors. Each human individual has distinct gut microbiota, even identical monozygotic twins do not have the same composition of gut microbes. Although much

of the individual variability remains unexplained, the main sources are thought to be mostly environmental, including diet, geography, lifestyle, or antibiotic use, but also include host genetics, age and early microbial exposure (Gilbert et al., 2018) (Pasolli et al., 2019) (Rothschild et al., 2018) (The Human Microbiome Project Consortium, 2012). Diet has been extensively studied in relation to the composition of the gut microbiota, and indeed there is evidence that it is essential in modulating the gut microbial community (De Filippo et al., 2010) (Ley et al., 2008) (Muegge et al., 2011).

Gut microbes perform many important functions in our bodies and are essential for human metabolism and overall health. Scientists are currently using two main models to understand the complex relationship between gut microbiota and human health and to further investigate the impact of these microbes on our physiology and the possible link between microbes and certain diseases. The first method is to use mice after treatment with broad-spectrum antibiotics, which results in mice with depleted gut microbes. However, the current gold standard in this field is the use of GF mice that are kept in special conditions without exposure to any microbes (Kennedy et al., 2018). This GF mouse can be colonized with a defined community of microbes to create a gnotobiotic mouse (Rosenbaum et al., 2015), which allows the microbiota to be studied in direct relation to specific conditions such as diet, drugs or a particular disease state.

Although the interindividual variability of gut microbial communities in terms of taxonomy is a well-known phenomenon, the gene composition and functional capacity of intestinal bacteria are highly conserved. Many phylogenetically distant bacteria carry similar genes and are therefore able to perform similar functions and produce similar metabolites (Tian et al., 2020). These metabolites provide an additional level of understanding of the relationship between host and microbiota beyond the classical characterization of microbial taxonomy or microbial genes. Metabolomics is therefore often involved in microbiome studies and provides a fingerprint of microbial functional status (Marcobal et al., 2013).

It is increasingly recognized that there is no one-size-fits-all diet and each individual responds differently to a particular dietary intervention, mainly due to the unique relationships between the host and its microbes. However, this connection is bi-directional and the possibility of shaping gut microbial communities and their functional potential through diet is emerging. Future studies must take into account these complex relationships and focus on the various cornerstones that determine personal responses – firstly, the diet of the individual with its essential food components and their vast array of products; secondly, the gut microbiota of the host, which consists

of hundreds of different species that influence a multitude of biological processes; and thirdly, the physiology and metabolism of the host itself, which is no easy task given the interdependence of these three key elements (Kolodziejczyk et al., 2019).

The human gut microbiota is relatively stable under normal conditions, but its composition can change rapidly due to dietary perturbations, albeit this shift is only transitional. However, a diet rich in a wide variety of plants is likely to support the growth of more bacterial groups, i.e., to increase diversity. The metabolic activity of the gut microbiota reflects the diet, i.e., the substrate provided, which is reflected by a change in the spectrum of metabolites produced.

So-called "multi-omics" data has revolutionized contemporary exploratory research by integrating more than one type of dataset into a single analysis using multiple approaches to understand one particular problem. This approach generates more data and therefore more information about a particular research topic can be obtained. This allows scientists to perform deeper analysis, see a more complete picture, and generate new insights into one complex biological problem because most biological processes are naturally interconnected. However, the biggest challenge is how to process this kind of data, which generates thousands of variables measured in a limited number of cases, resulting in highly multi-dimensional data. Different data sets need to be combined in a standardized way and appropriate computational tools have to be used to extract relevant variables that will be used to draw conclusions and generate new hypotheses. Nevertheless, with recent advances in bioinformatics and statistics including machine learning and regularization techniques, the analysis of high-dimensional data has been greatly simplified and continues to improve. It is no exaggeration to say that multi-omics studies are the future.

2   AIMS AND HYPOTHESES

The current state of knowledge points to a causal relationship between the composition of the gut microbiota and the development of many diseases of apparently different origin. Targeting the gut microbiota, either in composition or functional manifestations, could represent an effective therapeutic strategy. However, the wide implementation of this approach in therapeutic practice is still limited by the lack of knowledge about the behavior of such a complex system like the gut microbiome and its interaction with external stimuli and the host organism. The goal of this thesis is to enrich the knowledge in this area from several perspectives described below.

AIM 1:

To describe the microbiome and metabolome signature associated with a vegan diet.

Hypothesis

Long-term adherence to a vegan diet is associated with less incidence of non-communicable diseases (NCDs) like obesity, T2D, or cardiovascular disease. We hypothesize that at least some of the health benefits of a vegan diet could be explained by the composition and/or activity of gut microbiota.

AIM 2:

To develop an alternative tool for the estimation of specific function(s) of gut microbiota.

Hypothesis

The real-time quantitative PCR (qPCR) based method may serve as an alternative tool for the quantification of the specific gene across the whole bacterial population in the tested samples and therefore provide an insight into the functional capacity of the microbiota.

AIM 3:

To explore the possibilities of the manipulation of the gut microbiota by the dietary fiber inulin in the personalized treatment of T2D.

Hypothesis

The amount of fiber in the diet is one of the strongest environmental factors shaping the composition of gut microbiota but the results of clinical trials evaluating the effects of dietary fiber intervention in NCDs treatment are highly individually variable. We hypothesized that the outcome of the fiber intervention depends on the ability of the individual´s microbiota to process it and the potential beneficiaries of this treatment could be predicted based on the initial microbiome and metabolome characteristics.

AIM 4:

To assess the protective effect of the vegan microbiota against the influence of the obesogenic diet.

Hypothesis

We hypothesized that vegan microbiota may be protective against the effects of a western-type obesogenic diet and that its effect could be potentiated by the addition of dietary fiber inulin into the diet.

3 RESULTS AND COMMENTARY

3.1 Description of the microbiome and metabolome signature associated with a vegan diet

As highlighted in the introduction, diet is a crucial factor that shapes the gut microbiota. On the other hand, the gut microbial community is known for its resilience. Plant-based diets belong to nutritional trends gaining increasing attention both among the general population and nutrition specialists. These diets differ significantly from traditional omnivorous diets in many aspects. Due to their high content of microbiota-accessible carbohydrates, plant-based diets may lead to a shift in the composition of the gut microbiota towards that seen in traditional societies. Therefore, we performed a cross-sectional study comparing healthy vegans and omnivores microbiome and metabolome profiles and explored how the microbial composition or functional potential of gut microbiota differs between the groups with contrasting dietary habits.

This study compared the subjects of lean and healthy vegans (VG, n = 62) and omnivores (OM, n = 33). It involved collecting dietary records and measuring the macronutrient composition and fiber content. Stool samples were obtained from the participants for the untargeted metabolomic analysis (gas chromatography-mass spectrometry, GC-MS), bile acid spectrum determination, and microbial 16S rRNA (ribosomal ribonucleic acid) sequencing. The plasma was also analyzed for short-chain fatty acids (SCFAs) concentrations and untargeted metabolomics using liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR), respectively. Glucose and lipid homeostasis parameters were assessed as well. The level of systemic inflammation was estimated according to the serum concentration of C-reactive protein (CRP). These additional analyses provide a more comprehensive understanding of the metabolic effects of the diets being compared in the study.

The results of the 3-day prospective dietary records showed that omnivores had a higher daily intake of protein and lipids, while vegans had a higher intake of carbohydrates and dietary fiber. Compared with omnivores, vegans exhibited more favorable glucose homeostasis parameters, as evidenced by a lower concentration of glycated hemoglobin and lower secretion of insulin during the oral glucose tolerance test. Additionally, vegans had lower serum concentrations of total and low-density lipoprotein (LDL) cholesterol. Median serum CRP concentration was lower in vegans, although the values remained within the physiological range in both groups. These results suggest that a plant-based diet may offer benefits for glucose and lipid metabolism, as well as inflammation, compared to an omnivorous diet.

In terms of the microbial composition, permutational analysis of variance (PERMANOVA) tests revealed significant differences in β-diversity between vegans and omnivores at the order, family, and genus levels. However, the differences were relatively small, with only 15% of all bacteria being affected by diet at the genus level as determined by univariable analysis. When it comes to fecal metabolomics, we identified 146 different volatile organic compounds determined by GC-MC. We found that the vegan fecal metabolome was enriched in products of polysaccharide fermentation, such as SCFAs, while amino acid fermentation products were lower in the VG group. On the other hand, amino acid fermentation products such as indole, scatole, and p-cresol were higher in the OM group. VG and OM groups did not differ in primary bile acid spectrum composition, but vegans had significantly lower fecal content of one secondary bile acid, LCA, in feces compared with omnivores.

In the urine metabolome, we found higher concentrations of metabolites related to protein/amino acid metabolism in the OM group. The most significant changes between groups were observed in serum metabolomics, where we found a clear separation between the vegan and omnivore groups. The vegan serum metabolome was characterized by a higher content of SCFAs, dimethyl sulfone, and amino acids such as glycine, glutamine, asparagine, proline, and threonine, while the concentrations of branched-chain amino acids, their derivatives, and essential amino acid lysine were lower in the VG group.

These findings suggest that the differences in the diets of vegans and omnivores have a significant impact on their metabolome profiles, particularly in serum metabolome. The vegan diet was associated with a higher occurrence of potentially beneficial metabolites from dietary fiber fermentation products and a lower abundance of potentially harmful metabolites from amino acid fermentation products.

This article was published on the 7th of January 2022 in Frontiers in Nutrition, IF = 6.59

3.2 Development of an alternative method for the estimation of specific function(s) of gut microbiota

Although 16S rRNA sequencing is widely used to investigate the composition of bacterial communities in the gut, it does not provide insight into the functional aspects of these microorganisms and taxonomic resolution is in some cases insufficient. This knowledge gap has been addressed by the use of shotgun sequencing, which can provide a comprehensive view of the gut microbiota and its functional capacity. However, the high cost of this technique and relatively high requirements for bioinformatic skills has made it inaccessible to many laboratories. To address this problem, we focused on developing a simple and cost-effective method to estimate the functional capacity of butyrate synthesis by the gut microbiota. This method focuses on qPCR quantification of the bacterial gene encoding butyryl-CoA:acetate CoA-transferase, a key enzyme involved in butyrate synthesis. As the importance of butyrate in overall health is increasingly recognized, the proposed method may serve as a valuable tool for investigating the role of gut microbiota in health and disease.

As a first step towards developing a simple and inexpensive method to estimate the functional capacity of butyrate synthesis by the gut microbiota, we searched for human butyrate-producing gut bacteria whose genome contains *but* gene coding sequences. Thirty-six bacterial genomes containing the *but* gene were selected for further analysis, but due to the large variation in *but* coding sequences among the selected bacteria, it was not possible to design a single primer targeting all sequences at once. Therefore, six sets of degenerate primers targeting selected groups of bacteria were designed and validated based on bacterial phylogenetic distance and similarity of *but* gene sequences. All the primers were validated based on the length of their PCR products, where the predicted and observed lengths matched.

To quantify the qPCR results, a reference (housekeeping) gene had to be selected, which was a difficult task given the complexity of human stool. We compared two strategies. First, we used the 16S rRNA gene, which is universal to all bacteria and therefore inherently present in any sample. The target gene is quantified relative to the copy number of the 16S rRNA gene. The disadvantage of this approach is the variable number of 16S rRNA genes per genome in different bacteria, which may influence the results. The second strategy was based on a DNA spike whose sequences are not found in humans, such as the gene originating from the worm *Caenorhabditis elegans*. This method should be more precise but more demanding on labor and material. The target gene is quantified relative to the amount of spike DNA originating

from the *C. elegans* worm that was added prior to fecal DNA isolation. Surprisingly, copy numbers normalized against both the 16S rRNA gene and the *C. elegans* gene were correlated for all primer sets, which was also verified by the Bland-Altman method.

The developed was then applied to DNA (deoxyribonucleic acid) extracted from stool samples of a cohort of healthy lean vegans (VG, n = 63) and healthy obese omnivores (OB, n = 62) with known information about their fecal microbiota and metabolome composition. In both groups, the highest abundance of the *but* gene was found when using primers targeting cluster C of selected bacteria. Cluster C included the bacterial taxa *Faecalibacterium prausnitzii*, *Clostridium symbiosum*, *Clostridium* sp. M62/1 and three species belonging to the genus *Eubacterium*, and the VG group in this cluster differed significantly in *but* gene abundance from the OB group (Mann-Whitney U-test, p < 0.001). The abundance of the *but* gene determined by qPCR targeting all bacterial clusters correlated with results obtained previously from 16S rRNA sequencing. In addition, the higher copy number of the *but* gene in the VG group corresponded to the significantly higher amount of butyrate (Mann-Whitney U-test, p = 0.002) in respective fecal samples determined by NMR. Thus, our results support the hypothesis that the *but* gene copy number determination in bacterial DNA reflects its taxonomic composition, especially in the case of the more abundant bacteria, as well as a functional readout, in this case, the butyrate content of the feces.

In conclusion, this method may represent a powerful tool for estimating the functional capacity of the gut microbiota for butyrate synthesis based on qPCR quantification of bacterial butyryl-CoA:acetate CoA-transferase, provides deeper insight into the functional capacity of a particular sample, and could be useful for individual estimation of the utility of prebiotic therapy. This approach requires only equipment and skills commonly available in diagnostic laboratories and does not require advanced bioinformatic data analysis, making it a useful method for rapid screening of the specific functional capacity of the gut microbiota.

This article was published on the 2nd of September 2021 in Biomolecules, IF = 4.93

3.3   Exploration of the possibilities of the manipulation of gut microbiota by the dietary fiber inulin in the personalized treatment of T2D

Obesity and associated metabolic diseases, such as T2D, are major global health challenge, and the gut microbiota has been suggested to play a critical role in their development. Although many studies suggest an association between T2D and gut dysbiosis, results on the composition and function of the microbiota are inconsistent and sometimes contradictory. Diet plays an important role in shaping the microbiome, and dietary interventions focused on modulating the composition and/or performance of the gut microbiota appear to be a promising therapeutic target. This study aimed to determine whether the gut microbial composition and metabolome differ in lean healthy, obese healthy, and obese diabetic drug-naive T2D patients, whether the effects of inulin on glucose tolerance and insulin sensitivity can be explained by the response of the gut microbiota to inulin intervention, and whether this response can be predicted from the initial microbiome and metabolome signature.

The observational part of the study involved screening patients with pre/diabetes (DM, n = 49), metabolically healthy overweight/obese patients (OB, n = 66) and a lean healthy cohort (LH, n = 32). All cohorts had their blood, urine and stool samples collected. An oral glucose tolerance test (OGTT) was performed and 3-day prospected dietary records were obtained. The prospective part of the study involved 27 DM patients and the effect of inulin supplementation (10 g/day for three months) on glucose disposal and insulin sensitivity was investigated. Various outcomes were measured during the whole study, including gut microbial composition, SCFAs in plasma, volatile organic compounds (VOCs) in feces, and metabolites in serum measured by NMR.

Microbiome and metabolome composition varied across groups. The DM and LH groups represented opposite poles of the abundance spectrum, whereas OB was found to be more similar to DM. Concerning microbiome composition, multivariable statistics revealed significant differences in β-diversity between LH, OB, and DM phenotypes (PERMANOVA test). The univariable analysis identified 37 taxa that had significantly different abundance among the groups. A machine learning approach (Least Absolute Shrinkage and Selection Operator regression model, LASSO) was used to discriminate the groups based on microbial composition, but the outcome was not satisfactory. When OB and DM data sets were grouped, the accuracy of the model increased to 75%. Significant differences were also found in the β-diversity of VOCs between the groups, with pairwise analysis confirming significant differences between OB and DM groups compared to the LH group. Univariable analysis revealed ten VOCs

with significantly different abundance between groups. Nonanoic acid was more abundant, while all other compounds, including SCFAs esters, were less abundant in the OB and DM groups compared to LH controls. The LASSO model based on serum metabolome data was able to classify unknown subjects into the categories LH, OB, or DM with an accuracy of 74%. The integrated LASSO model, which combined all variables, allowed better classification between groups, with an accuracy of 77%. Taken together, our results demonstrate that microbiome and metabolome composition differ between lean participants and subjects with obesity, but do not allow to discriminate between obese subjects with and without diabetes.

Inulin supplementation in 27 subjects with obesity and diabetes led to a significant change in their microbiota composition (PERMANOVA <0.001). Several bacterial taxa, including butyrate producers such as *Faecalibacterium*, *Anaerostipes* or *Eubacterium halii* and other bacteria considered beneficial such as *Lactobacillus*, *Bifidobacterium* and *Akkermansia*, increased after treatment. Conversely, some bacterial taxa abundances decreased after supplementation, for example, those known to be associated with protein fermentation. After the inulin treatment, there was a significant increase in the concentration of butyric acid, propionic acid, and asparagine in the serum, while the concentration of glycerol and 2-propanol decreased. Inulin intake also affected markers of glucose tolerance and insulin sensitivity, but the individual response varied greatly. Nevertheless, significant improvement in glucose tolerance (measured as 120 min OGTT glucose) was observed in the entire group that received the intervention, along with a tendency towards a reduction in the area under the curve (AUC) for OGTT glucose and fasting glycemia. Linear regression models were fitted with all glucose metabolism parameters as outcome variables and all omics and clinical variables as predictors. We identified potential predictors of individual response to inulin treatment independently on pre-intervention glycemic parameters, such as serum BCAA derivatives, serum 3-hydroxyisobutyrate, fecal indole, and various bacterial taxa.

In conclusion, this study provides valuable insights into the role of gut microbiota in the development of metabolic diseases and the potential use of dietary interventions to modulate the microbiota and improve metabolic health. The findings highlight the complex nature of microbial changes underlying the development of TD2 and obesity but also suggest that inulin supplementation can lead to significant improvements in glucose tolerance and insulin sensitivity, as well as changes in microbiota composition and metabolome. These findings may help personalize treatment options and improve outcomes for patients with metabolic diseases who have struggled to achieve success through lifestyle changes alone.

3.4   Assessment of the protective effect of vegan microbiota against the influence of the obesogenic diet

As described in the introductory section, gut microbiota plays an essential role in energy homeostasis, weight control, and inflammation, which are all related to NCDs like obesity, T2D or non-alcoholic fatty liver disease NAFLD. Targeted modulation of gut microbiota and its metabolic programming is considered a potentially promising therapeutic approach in the NCDs treatment but more research on this topic is definitely needed. Fecal microbial transfer (FMT) is gaining more attention due to its potential therapeutic properties through altering the entire microbial community. As noted above, vegan or plant-based diets are associated with beneficial effects on overall health, suggesting that vegan microbiota might be desirable, and subjects adhering to plant-based diets should be explored as suitable candidates for FMT donors. However, it remains unclear how the transferred microbiota is affected by the host diet and the substrates provided.

In this study, stool from four vegan donors was used to prepare a mixed VG inoculum used for FMT transfer to GF animals. Female GF mice were colonized with VG inoculum and were paired with male GF mice. Their offspring were further used for the experiment when ex-GF humanized mice (VG) were fed either a Western-type diet (WD) or a standard diet (SD) with or without the addition of inulin (I). The same experimental design was used in conventional mice (CV). The objectives of this study were to determine whether and how the vegan microbiota may have a protective effect against an obesogenic diet, to describe the mechanistic relationships of microbiome and metabolome in these mice, and to explore the effect of fiber in enhancing the additional therapeutic potential of the vegan microbiota.

After an eight-week experimental period on specific diets, glucose and lipid homeostasis parameters, fecal microbiota composition and serum and fecal metabolome were determined. Western diet caused a significant increase in total body weight and liver triacylglycerol content in both mice models (Kruskal–Wallis test and Dunn's post hoc test with the Benjamin–Hochberg correction, $p < 0.05$). Impaired glucose homeostasis caused by the Western diet was observed only in the VG group.   Inulin supplementation reversed the liver steatosis and improved glucose homeostasis in the VG group, but not in the CV group, so further analyses focused on the VG

group only. Regarding microbiota in the VG group, pairwise PERMANOVA analysis on the taxonomic level species showed significant differences between all dietary groups (SD vs SD + I p = 0.0011, SD vs WD p = 0.0011, SD vs WD + I p = 0.0011, WD vs WD + I p = 0.0042). The LASSO machine learning regression model was able to classify bacteria at the species level between all pairs of groups with at least 90% accuracy, sensitivity and specificity.

Untargeted metabolome analysis identified 61 VOCs in cecum content. Inulin supplementation did not lead to an alteration of cecum metabolome in the SD diet group (paired PERMANOVA, p > 0.1), but resulted in a significant change in the WD group (paired PERMANOVA, p = 0.005). Interestingly, after inulin supplementation, we observed a shift from amino acid fermentative metabolism to saccharolytic fermentation described by a decrease of the product of tryptophan fermentation indole (only in VG_SD+I group), a decrease of methionine/cysteine fermentation product dimethyl trisulfide (in both VG_SD+I and VG_WD+I groups), an increase of butyrate (only in VG_SD+I group) and increase of acetic acid (in both VG_SD+I and VG_WD+I groups). The serum metabolome assessed by NMR spectroscopy was not significantly affected by any of the treatments. Paired PERMANOVA analysis revealed no difference between groups (all paired PERMANOVA tests > 0.15).

In this animal model, we demonstrated that vegan microbiota alone may not be sufficient to counteract the negative metabolic effects of a Western-type diet. However, further supplementation by dietary fiber (in this case inulin) can protect from steatosis and impairment of glucose metabolism. Notably, this effect was only observed in humanized mice and not in conventional mice models. Furthermore, inulin supplementation in humanized mice model led to a shift in the cecal microbial community and its metabolic performance. These results suggest that the treatment of metabolic disorders by FMT should be also supported by subsequent dietary precautions in order for the treatment to be more successful.

This article was published on the 15th of January 2023 in Nutrients, IF = 6.71

4 GENERAL DISCUSSION AND FUTURE PERSPECTIVES

This dissertation thesis addresses the possible modification of the composition of the gut microbiota by diet not only from a taxonomic but also from a functional point of view, by incorporating metabolomics into the analyses and developing a new method to estimate the ability of the microbiota to produce the beneficial metabolite butyrate. The theoretical part of the thesis summarizes the importance of gut microbes for human health. In particular, it discusses the immersive functions of gut microbiota, its impact on human development and it also summarizes current knowledge on manipulating the gut microbiome through diet. It highlights the most reputable research that has been conducted in this area. In addition, some of the most commonly used multi-omics methods are introduced and their integration is briefly explained. The experimental part of the thesis focuses on four monothematic articles that have been published in connection with this work.

The first study describes the microbiome and metabolome profiles of healthy lean vegans and omnivores and explores the impact of plant-based diet on microbial function and to a lesser extent, microbial taxonomic composition. The study involved collecting dietary records and analyzing stool and plasma samples for various analyses such as metabolomics, bile acid spectrum determination, the SCFAs contents measurement, 16S rRNA sequencing, glucose and lipid homeostasis, and inflammation parameters. The study found that the vegan diet was associated with a higher intake of carbohydrates and dietary fiber, more favorable glucose and lipid metabolism, and lower inflammation levels compared to the omnivorous diet. The metabolome profiles differed significantly between the groups, with vegans having a higher occurrence of potentially beneficial metabolites from dietary fiber fermentation and a lower abundance of potentially harmful metabolites from amino acid fermentation products. The study highlights the importance of plant-based diets by demonstrating their positive impact on microbial function, metabolic health, and inflammation levels compared to omnivorous diets.

The second study presented a simple and cost-effective method for estimating the functional capacity of butyrate synthesis by the gut microbiota, an important process for maintaining overall health. The method involves the use of qPCR to quantify the bacterial gene encoding butyryl-CoA:acetate CoA-transferase, a key enzyme involved in butyrate synthesis, and was validated using six sets of degenerate primers. We compared two strategies for normalizing qPCR results and found that copy numbers normalized to the 16S rRNA gene and the *C. elegans*-derived DNA spike were comparable for all primer sets. We then tested the method on stool samples from

healthy lean vegans and healthy obese omnivores and found that the amount of the *but* gene in the VG group was significantly different from the OB group, corresponding to significantly higher amounts of butyrate in the respective stool samples as determined by NMR. Thus, the method may represent a powerful tool for estimating the functional capacity of the gut microbiota and could be useful for individual assessment of the utility of prebiotic or dietary treatment.

The third study investigated whether gut microbiota composition and metabolome differ in lean healthy, obese healthy, and obese diabetic T2D patients without medication and whether the effects of inulin on glucose tolerance and insulin sensitivity can be explained by the response of the gut microbiota to inulin intervention and whether this response can be predicted from the initial microbiome and metabolome signature. The study found that the composition of microbiome and metabolome differed between lean participants and obese subjects, but did not distinguish well obese subjects with and without diabetes. Inulin supplementation resulted in a significant change in microbiota composition, with an increase in beneficial bacterial taxa and a decrease in potentially harmful ones. Inulin intake also affected markers of glucose tolerance and insulin sensitivity, and potential predictors of individual response to inulin treatment were identified. These findings highlight the complex character of the gut microbiota and host metabolism response to inulin intervention and demonstrated the possibilities of personalized therapeutic microbiota manipulation.

In the fourth study, stool samples from four vegan donors were used to prepare a mixed inoculum for FMT to create humanized ex-GF mice. The aim was to investigate the protective effects of the vegan microbiota against the Western-type diet and the role of dietary fiber (inulin) in enhancing its therapeutic potential. The study found that the Western diet caused significant weight gain and triacylglycerol content in the liver in both humanized and conventional mouse models, but impaired glucose homeostasis was observed only in the humanized group. Inulin supplementation reversed liver steatosis and improved glucose homeostasis in the humanized mice group but not in the conventional mice group. The study suggests that a vegan microbiota alone may not be sufficient to counteract the negative metabolic effects of a Western-style diet, but follow-up dietary support may substantially enhance the treatment success.

This thesis concludes by highlighting the importance of gut microbiota for human health and the opportunity for dietary interventions that can influence microbial composition and function. The first study demonstrated that adherence to a plant-based diet high

in carbohydrates and fiber can lead to a favorable microbial profile and metabolome associated with improved glucose and lipid metabolism and lower levels of inflammation. The second study presented a new method to estimate the functional capacity of butyrate synthesis by the gut microbiota. The third study focused on the identification of predictors of the therapeutic efficacy of inulin treatment in (pre)diabetes. Finally, a fourth study used FMT to investigate the protective effects of vegan microbiota against a Western-style diet and found that fiber may enhance the therapeutic potential of FMT. Overall, these studies highlight the potential of personalized dietary interventions to modify gut microbiota and improve metabolic health, but further research is needed to confirm these findings.

5   CONCLUSIONS

AIM 1:

We have shown that the composition of the gut microbiota of healthy lean long-term vegans and omnivores does not differ dramatically. In contrast, vegans and omnivores significantly differ in the composition of the fecal, serum, and urine metabolomes, probably as an effect of different availability of dietary substrates. Consequently, the vegan diet was associated with a lower abundance of the potentially harmful (protein fermentation products) and a higher occurrence of potentially beneficial (dietary fiber fermentation products) metabolites in feces.

AIM 2:

We developed a method for the assessment of the functional capacity of gut microbiota for butyrate synthesis based on the qPCR quantification of bacterial butyryl-CoA:acetate CoA-transferase. This method is based on qPCRs using degenerate primers specific for *but* gene variants and quantification of but gene abundance using the selected reference gene (16S rRNA gene or spike UNC-6 gene from *C. elegans*).

AIM 3:

In patients with newly diagnosed pre/diabetes treated with inulin, we observed considerable interindividual variability in the effects of inulin treatment on glucose homeostasis. We identified several omics-derived biomarkers that may play a central role in the development of obesity-associated metabolic changes and identified several predictors of treatment efficiency.

AIM 4:

Using the model of ex-GF mice humanized with mixed human vegan microbiota we found that it does not protect against the adverse effects of a Western-type diet like obesity, liver steatosis, and compromised glucose homeostasis. In contrast, supplementation of the Western diet with inulin reversed steatosis and ameliorated glucose metabolism, though it did not affect weight gain in this model. Inulin supplementation resulted in a significant change in the gut microbiota composition and its metabolic performance, inducing the shift from proteolytic towards saccharolytic fermentation. In the context of the potential use of fecal microbiota transfer with vegan microbiota in the therapy of metabolic NCDs, our study points out that it is not only the particular microbiota transfer but also the following dietary intervention with inulin or other dietary fiber and/or dietary change that is necessary for therapeutic success.

6 ABBREVIATIONS

AUC	area under the curve
C. elegans	*Caenorhabditis elegans*
CRP	C-reactive protein
DNA	deoxyribonucleic acid
FMT	fecal microbial transfer
GC-MS	gas chromatography-mass spectrometry
GF	germ-free
GIT	gastrointestinal tract
LASSO	Least Absolute Shrinkage and Selection Operator
LC-MS	liquid chromatography-mass spectrometry
LDL	low-density lipoprotein
NAFLD	non-alcoholic fatty liver disease
NCDs	non-communicable diseases
NMR	nuclear magnetic resonance spectroscopy
OGTT	oral glucose tolerance test
PCR	polymerase chain reaction
PERMANOVA	Permutational Analysis of Variance
qPCR	quantitative PCR
RNA	ribonucleic acid
rRNA	ribosomal RNA
SCFAs	short-chain fatty acids
T2D	type 2 diabetes
VOCs	volatile organic compounds
WD	Western-type diet

7 REFERENCES

Adak, A., & Khan, M. R. (2019). An insight into gut microbiota and its functionalities. *Cellular and Molecular Life Sciences*, *76*(3), 473–493. https://doi.org/10.1007/s00018-018-2943-4

Agus, A., Clément, K., & Sokol, H. (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. *Gut*, *70*(6), 1174–1182. https://doi.org/10.1136/gutjnl-2020-323071

Agus, A., Denizot, J., Thévenot, J., Martinez-Medina, M., Massier, S., Sauvanet, P., Bernalier-Donadille, A., Denis, S., Hofman, P., Bonnet, R., Billard, E., & Barnich, N. (2016). Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. *Scientific Reports*, *6*(December 2015), 1–14. https://doi.org/10.1038/srep19032

Amieva, M., Alto, P., & Alto, P. (2016). Pathobiology of Helicobacter pylori-induced Gastric Cancer. *Gastroenterology*, *150*(1), 64–78. https://doi.org/10.1053/j.gastro.2015.09.004

Anand, S., & Mande, S. S. (2018). Diet, microbiota and gut-lung connection. *Frontiers in Microbiology*, *9*(SEP). https://doi.org/10.3389/fmicb.2018.02147

Arany, Z., & Neinast, M. (2018). Branched Chain Amino Acids in Metabolic Disease Do Elevations in BCAAs Cause Insulin. *Current Diabetes Reports*, *18*(76), 1–8.

Audebert, C., Even, G., Cian, A., Blastocystis Investigation Group, Loywick, A., Merlin, S., Viscogliosi, E., Chabé, M., El Safadi, D., Certad, G., Delhaes, L., Pereira, B., Nourrisson, C., Poirier, P., Wawrzyniak, I., Delbac, F., Morelle, C., Bastien, P., Lachaud, L., … Rabodonirina, M. (2016). Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. *Scientific Reports*, *6*(February), 1–11. https://doi.org/10.1038/srep25255

Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Gou, Y. K., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National Academy of Sciences of the United States of America*, *101*(44), 15718–15723. https://doi.org/10.1073/pnas.0407076101

Baldeon, A. D., McDonald, D., Gonzalez, A., Knight, R., & Holscher, H. D. (2023). Diet Quality and the Fecal Microbiota in Adults in the American Gut Project Authors: *The Journal of Nutrition*. https://doi.org/10.1016/j.tjnut.2023.02.018

Be, C., Marteau, P., Pochart, P., & Inserm, U. (2001). *Comparative Study of Bacterial Groups within the Human Cecal and Fecal Microbiota*. *67*(10), 4939–4942. https://doi.org/10.1128/AEM.67.10.4939

Biagi, E., Franceschi, C., Rampelli, S., Severgnini, M., Ostan, R., Turroni, S., Consolandi, C., Quercia, S., Scurti, M., Monti, D., Capri, M., Brigidi, P., & Candela, M. (2016). Gut Microbiota and Extreme Longevity. *Current Biology*, *26*(11), 1480–1485. https://doi.org/10.1016/j.cub.2016.04.016

Blaser, M. J., & Falkow, S. (2009). What are the consequences of the disappearing human microbiota? *Nature Reviews Microbiology*, *7*(12), 887–894. https://doi.org/10.1038/nrmicro2245

Boland, M. (2016). Human digestion - a processing perspective. *Journal of the Science of Food and Agriculture*, *96*(7), 2275–2283. https://doi.org/10.1002/jsfa.7601

Bordenstein, S. R., & Theis, K. R. (2015). Host biology in light of the microbiome: Ten principles of holobionts and hologenomes. *PLoS Biology*, *13*(8), 1–23. https://doi.org/10.1371/journal.pbio.1002226

Bustamante, C. D., De La Vega, F. M., & Burchard, E. G. (2011). Genomics for the world. *Nature*, *475*(7355), 163–165. https://doi.org/10.1038/475163a

Callahan, B. J., McMurdie, P. J., & Holmes, S. P. (2017). Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. *ISME Journal*, *11*(12), 2639–2643. https://doi.org/10.1038/ismej.2017.119

Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Lozupone, C. A., Turnbaugh, P. J., Fierer, N., & Knight, R. (2011). Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proceedings*

of the National Academy of Sciences of the United States of America, *108*(SUPPL. 1), 4516–4522. https://doi.org/10.1073/pnas.1000080107

Caruso, V., Song, X., Asquith, M., & Karstens, L. (2019). Performance of Microbiome Sequence Inference Methods in Environments with Varying Biomass. *MSystems*, *4*(1). https://doi.org/10.1128/msystems.00163-18

Celis, A. I., Aranda-Díaz, A., Culver, R., Xue, K., Relman, D., Shi, H., & Huang, K. C. (2022). Optimization of the 16S rRNA sequencing analysis pipeline for studying in vitro communities of gut commensals. *IScience*, *25*(4). https://doi.org/10.1016/j.isci.2022.103907

Chaudhari, D. S., Dhotre, D. P., Agarwal, D. M., Gaike, A. H., Bhalerao, D., Jadhav, P., Mongad, D., Lubree, H., Sinkar, V. P., Patil, U. K., Salvi, S., Bavdekar, A., Juvekar, S. K., & Shouche, Y. S. (2020). Gut, oral and skin microbiome of Indian patrilineal families reveal perceptible association with age. *Scientific Reports*, *10*(1), 1–13. https://doi.org/10.1038/s41598-020-62195-5

Chen, C., Song, X., Wei, W., Zhong, H., Dai, J., Lan, Z., Li, F., Yu, X., Feng, Q., Wang, Z., Xie, H., Chen, X., Zeng, C., Wen, B., Zeng, L., Du, H., Tang, H., Xu, C., Xia, Y., … Jia, H. (2017). The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. *Nature Communications*, *8*(1). https://doi.org/10.1038/s41467-017-00901-0

Chen, X., Lu, Y., Chen, T., & Li, R. (2021). The Female Vaginal Microbiome in Health and Bacterial Vaginosis. *Frontiers in Cellular and Infection Microbiology*, *11*(April), 1–15. https://doi.org/10.3389/fcimb.2021.631972

Chen, Y., Wu, F. H., Wu, P. Q., Xing, H. Y., & Ma, T. (2022). The Role of The Tumor Microbiome in Tumor Development and Its Treatment. *Frontiers in Immunology*, *13*(July), 1–15. https://doi.org/10.3389/fimmu.2022.935846

Chiarello, M., McCauley, M., Villéger, S., & Jackson, C. R. (2022). Ranking the biases: The choice of OTUs vs. ASVs in 16S rRNA amplicon data analysis has stronger effects on diversity measures than rarefaction and OTU identity threshold. *PLoS ONE*, *17*(2 February), 1–19. https://doi.org/10.1371/journal.pone.0264443

Chong, J., & Xia, J. (2017). Computational approaches for integrative analysis of the metabolome and microbiome. *Metabolites*, *7*(4). https://doi.org/10.3390/metabo7040062

Clarke, S. F., Murphy, E. F., Sullivan, O. O., Lucey, A. J., Humphreys, M., Hogan, A., Hayes, P., Reilly, M. O., Jeffery, I. B., Wood-martin, R., Kerins, D. M., Quigley, E., Ross, R. P., Toole, P. W. O., Molloy, M. G., Falvey, E., Shanahan, F., & Cotter, P. D. (2014). *Exercise and associated dietary extremes impact on gut microbial diversity*. 1913–1920. https://doi.org/10.1136/gutjnl-2013-306541

Clarridge, J. E. (2004). Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. *Clinical Microbiology Reviews*, *17*(4), 840–862. https://doi.org/10.1128/CMR.17.4.840-862.2004

Clemente, J. C., Pehrsson, E. C., Blaser, M. J., Sandhu, K., Gao, Z., Wang, B., Magris, M., Hidalgo, G., Contreras, M., Noya-Alarcón, Ó., Lander, O., McDonald, J., Cox, M., Walter, J., Oh, P. L., Ruiz, J. F., Rodriguez, S., Shen, N., Song, S. J., … Dominguez-Bello, M. G. (2015). The microbiome of uncontacted Amerindians. *Science Advances*, *1*(3). https://doi.org/10.1126/sciadv.1500183

Conesa, A., & Beck, S. (2019). Making multi-omics data accessible to researchers. *Scientific Data*, *6*(1), 4–7. https://doi.org/10.1038/s41597-019-0258-4

Cover, T. L., & Blaser, M. J. (2009). Helicobacter pylori in health and disease. *Gastroenterology*, *136*(6), 1863–1873. https://doi.org/10.1053/j.gastro.2009.01.073

Craig Venter, J., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., Amanatides, P., Ballew, R. M., Huson, D. H., Wortman, J. R., Zhang, Q., Kodira, C. D., Zheng, X. H., Chen, L., … Zhu, X. (2001). The sequence of the human genome. *Science*, *291*(5507), 1304–1351. https://doi.org/10.1126/science.1058040

Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P. E., & MacFarlane, G. T. (1987). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut*, *28*, 1221–1227. https://doi.org/10.1136/gut.28.10.1221

Appendix no. 1

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V, Devlin, A. S., Varma, Y., Fischbach, M. A., Biddinger, S. B., Dutton, R. J., & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature*, *505*(7484), 559–563. https://doi.org/10.1038/nature12820

De Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013). Pleiotropic roles of bile acids in metabolism. *Cell Metabolism*, *17*(5), 657–669. https://doi.org/10.1016/j.cmet.2013.03.013

De Angelis, M., Ferrocino, I., Calabrese, F. M., De Filippis, F., Cavallo, N., Siragusa, S., Rampelli, S., Di Cagno, R., Rantsiou, K., Vannini, L., Pellegrini, N., Lazzi, C., Turroni, S., Lorusso, N., Ventura, M., Chieppa, M., Neviani, E., Brigidi, P., O'Toole, P. W., … Cocolin, L. (2020). Diet influences the functions of the human intestinal microbiome. *Scientific Reports*, *10*(1), 4247. https://doi.org/10.1038/s41598-020-61192-y

De Filippo, C., Cavalieri, D., Di, M., Ramazzotti, M., & Baptiste, J. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *PNAS*, *107*(33), 14691–14696. https://doi.org/10.1073/pnas.1005963107

De Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022). Gut microbiome and health: Mechanistic insights. *Gut*, 1020–1032. https://doi.org/10.1136/gutjnl-2021-326789

Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., & Knight, R. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proceedings of the National Academy of Sciences of the United States of America*, *107*(26), 11971–11975. https://doi.org/10.1073/pnas.1002601107

Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019). Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. *Microbiology and Molecular Biology Reviews*, *83*(3), 1–29. https://doi.org/10.1128/mmbr.00007-19

Fragiadakis, G. K., Smits, S. A., Sonnenburg, E. D., Van Treuren, W., Reid, G., Knight, R., Manjurano, A., Changalucha, J., Dominguez-Bello, M. G., Leach, J., & Sonnenburg, J. L. (2019). Links between environment, diet, and the hunter-gatherer microbiome. *Gut Microbes*, *10*(2), 216–227. https://doi.org/10.1080/19490976.2018.1494103

Gallo, R. L. (2017). Human Skin Is the Largest Epithelial Surface for Interaction with Microbes. *J Invest Dermatol.*, *137*(6), 1213–1214. https://doi.org/10.1016/j.jid.2016.11.045

Gilbert, J., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, V. S., & Knight, R. (2018). Current understanding of the human microbiome. *Nat Med.*, *24*(4), 392–400. https://doi.org/10.1038/nm.4517

Goffau, M. C. De, Lager, S., Sovio, U., Gaccioli, F., Peacock, S. J., Parkhill, J., Charnock-jones, D. S., & Smith, C. S. (2019). Human placenta has no microbiome but can harbour potential pathogens. *Nature*, *572*(7769), 329–334. https://doi.org/10.1038/s41586-019-1451-5

Gojda, J., & Cahova, M. (2021). Gut microbiota as the link between elevated bcaa serum levels and insulin resistance. *Biomolecules*, *11*(10), 1–16. https://doi.org/10.3390/biom11101414

Gomaa, E. Z. (2020). Human gut microbiota/microbiome in health and diseases: a review. *Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology*, *113*(12), 2019–2040. https://doi.org/10.1007/s10482-020-01474-7

Goodrich, J. K., Davenport, E. R., Beaumont, M., Jackson, M. A., Knight, R., Ober, C., Spector, T. D., Bell, J. T., Clark, A. G., & Ley, R. E. (2016). Genetic Determinants of the Gut Microbiome in UK Twins. *Cell Host and Microbe*, *19*(5), 731–743. https://doi.org/10.1016/j.chom.2016.04.017

Gu, Z., Eils, R., & Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics*, *32*(May), 2847–2849. https://doi.org/10.1093/bioinformatics/btw313

Guinane, M. C., Tadrous, A., Fouhy, F., Ryan, C. A., Dempsey, E. M., Murphy, B., Andrews, E., Cotter, P. D., Stanton, C., & Ross, R. P. (2013). Microbial Composition of Human Appendices from Patients following. *MBio*, *4*(1), 1–6. https://doi.org/10.1128/mBio.00366-12.Editor

Appendix no. 1

Guzior, D. V., & Quinn, R. A. (2021). Review: microbial transformations of human bile acids. *Microbiome*, *9*(1), 1–13. https://doi.org/10.1186/s40168-021-01101-1

Hamada, H., Hiroi, T., Nishiyama, Y., Takahashi, H., Masunaga, Y., Hachimura, S., Kaminogawa, S., Takahashi-Iwanaga, H., Iwanaga, T., Kiyono, H., Yamamoto, H., & Ishikawa, H. (2002). Identification of Multiple Isolated Lymphoid Follicles on the Antimesenteric Wall of the Mouse Small Intestine. *The Journal of Immunology*, *168*(1), 57–64. https://doi.org/10.4049/jimmunol.168.1.57

Hanlon, D. E. O., Moench, T. R., & Cone, R. A. (2013). *Vaginal pH and Microbicidal Lactic Acid When Lactobacilli Dominate the Microbiota*. *8*(11), 1–8. https://doi.org/10.1371/journal.pone.0080074

Harmsen, H. J. M., Wildeboer-Veloo, A. C. M., Raangs, G. C., Wagendorp, A. A., Klijn, N., Bindels, J. G., & Welling, G. W. (2000). Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. *Journal of Pediatric Gastroenterology and Nutrition*, *30*(1), 61–67. https://doi.org/10.1097/00005176-200001000-00019

Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology*, *18*(1), 1–15. https://doi.org/10.1186/s13059-017-1215-1

Hill, M. J. (1997). Intestinal flora and endogenous vitamin synthesis. In *European Journal of Cancer Prevention* (Vol. 6, pp. S43–S45). https://doi.org/10.1097/00008469-199703001-00009

Hunt, R. H., Camilleri, M., Crowe, S. E., El-Omar, E. M., Fox, J. G., Kuipers, E. J., Malfertheiner, P., McColl, K. E. L., Pritchard, D. M., Rugge, M., Sonnenberg, A., Sugano, K., & Tack, J. (2015). The stomach in health and disease. *Gut*, *64*(10), 1650–1668. https://doi.org/10.1136/gutjnl-2014-307595

James, K. R., Gomes, T., Elmentaite, R., Kumar, N., Gulliver, E. L., King, H. W., Stares, M. D., Bareham, B. R., Ferdinand, J. R., Velislava, N., Polański, K., Forster, S. C., Jarvis, L. B., Suchanek, O., Howlett, S., James, L. K., Jones, J. L., Meyer, K. B., & Menna, R. (2020). *Europe PMC Funders Group Distinct microbial and immune niches of the human colon*. *21*(3), 343–353. https://doi.org/10.1038/s41590-020-0602-z.Distinct

Janda, J. M., & Abbott, S. L. (2007). 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: Pluses, perils, and pitfalls. *Journal of Clinical Microbiology*, *45*(9), 2761–2764. https://doi.org/10.1128/JCM.01228-07

Jha, A. R., Davenport, E. R., Gautam, Y., Bhandari, D., Tandukar, S., Ng, K. M., Fragiadakis, G. K., Holmes, S., Gautam, G. P., Leach, J., Sherchand, J. B., Bustamante, C. D., & Sonnenburg, J. L. (2018). Gut microbiome transition across a lifestyle gradient in Himalaya. *PLoS Biology*, *16*(11), 1–30. https://doi.org/10.1371/journal.pbio.2005396

Jiang, D., Armour, C. R., Hu, C., Mei, M., & Tian, C. (2019). Microbiome Multi-Omics Network Analysis : Statistical Considerations , Limitations , and Opportunities. *Frontiers in Genetics*, *10*(November), 1–19. https://doi.org/10.3389/fgene.2019.00995

Johansson, M. E. V., Holmén Larsson, J. M., & Hansson, G. C. (2011). The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proceedings of the National Academy of Sciences of the United States of America*, *108*(SUPPL. 1), 4659–4665. https://doi.org/10.1073/pnas.1006451107

Johansson, M. E. V., Jakobsson, H. E., Holmén-Larsson, J., Schütte, A., Ermund, A., Rodríguez-Piñeiro, A. M., Arike, L., Wising, C., Svensson, F., Bäckhed, F., & Hansson, G. C. (2015). Normalization of host intestinal mucus layers requires long-term microbial colonization. *Cell Host Microbe*, *18*(5), 582–592. https://doi.org/10.1016/j.chom.2015.10.007

Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M., & Marchesi, J. R. (2008). Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. *Proceedings of the National Academy of Sciences of the United States of America*, *105*(36), 13580–13585. https://doi.org/10.1073/pnas.0804437105

Kalbermatter, C., Fernandez Trigo, N., Christensen, S., & Ganal-Vonarburg, S. C. (2021). Maternal Microbiota, Early Life Colonization and Breast Milk Drive Immune Development in the Newborn. *Frontiers in Immunology*,

12(May), 1–22. https://doi.org/10.3389/fimmu.2021.683022

Kang, M., Ko, E., & Mersha, T. B. (2022). A roadmap for multi-omics data integration using deep learning. *Briefings in Bioinformatics*, *23*(1), 1–16. https://doi.org/10.1093/bib/bbab454

Kennedy, E. A., King, K. Y., & Baldridge, M. T. (2018). Mouse microbiota models: Comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria. *Frontiers in Physiology*, *9*(OCT), 1–16. https://doi.org/10.3389/fphys.2018.01534

Kim, Y. S., & Ho, S. B. (2010). Intestinal goblet cells and mucins in health and disease: Recent insights and progress. *Current Gastroenterology Reports*, *12*(5), 319–330. https://doi.org/10.1007/s11894-010-0131-2

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, *165*(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041

Kolodziejczyk, A. A., Zheng, D., & Elinav, E. (2019). Diet–microbiota interactions and personalized nutrition. *Nature Reviews Microbiology*, *17*(12), 742–753. https://doi.org/10.1038/s41579-019-0256-8

Kumar, J., Rani, K., & Datt, C. (2020). Molecular link between dietary fibre, gut microbiota and health. *Molecular Biology Reports*, *47*(8), 6229–6237. https://doi.org/10.1007/s11033-020-05611-3

Kundu, P., Blacher, E., Elinav, E., & Pettersson, S. (2017). Our Gut Microbiome: The Evolving Inner Self. *Cell*, *171*(7), 1481–1493. https://doi.org/10.1016/j.cell.2017.11.024

Land, M., Hauser, L., Jun, S., Nookaew, I., Leuze, M. R., Ahn, T., Karpinets, T., Lund, O., & Kora, G. (2015). *Insights from 20 years of bacterial genome sequencing*. 141–161. https://doi.org/10.1007/s10142-015-0433-4

Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., Fitzhugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., Levine, R., McEwan, P., … Chen, Y. J. (2001). Initial sequencing and analysis of the human genome. *Nature*, *412*(6846), 565–566. https://doi.org/10.1038/35087627

LeBlanc, J. G., Milani, C., de Giori, G. S., Sesma, F., van Sinderen, D., & Ventura, M. (2013). Bacteria as vitamin suppliers to their host: A gut microbiota perspective. *Current Opinion in Biotechnology*, *24*(2), 160–168. https://doi.org/10.1016/j.copbio.2012.08.005

Lederberg, B. J., & McCray, A. T. (2001). 'Ome Sweet' Omics-- A Genealogical Treasury of Words. *The Scientist*, *15*(7), 8.

Lee-Sarwar, K. A., Lasky-Su, J., Kelly, R. S., Litonjua, A. A., & Weiss, S. T. (2020). Metabolome–microbiome crosstalk and human disease. *Metabolites*, *10*(5), 1–10. https://doi.org/10.3390/metabo10050181

Lee, Y. S., Kim, T. Y., Kim, Y., Lee, S. H., Kim, S., Kang, S. W., Yang, J. Y., Baek, I. J., Sung, Y. H., Park, Y. Y., Hwang, S. W., Eunju, O., Kim, K. S., Liu, S., Kamada, N., Gao, N., & Kweon, M. N. (2018). Microbiota-Derived Lactate Accelerates Intestinal Stem-Cell-Mediated Epithelial Development. *Cell Host and Microbe*, *24*(6), 833-846.e6. https://doi.org/10.1016/j.chom.2018.11.002

Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P., Roy, R., Bircher, J. S., Schlegel, M. L., Tucker, T. A., Mark, D., Knight, R., & Gordon, J. I. (2008). Evolution of mammals and their gut microbes. *Science*, *320*(5883), 1647–1651. https://doi.org/10.1126/science.1155725

Li, T., & Chiang, J. Y. L. (2015). Bile acids as metabolic regulators. *Current Opinion in Gastroenterology*, *31*(2), 159–165. https://doi.org/10.1097/MOG.0000000000000156

Li, X., Liu, Y., Yang, X., Li, C., & Song, Z. (2022). The Oral Microbiota: Community Composition, Influencing Factors, Pathogenesis, and Interventions. *Frontiers in Microbiology*, *13*(April), 1–19. https://doi.org/10.3389/fmicb.2022.895537

Link, C. D. (2021). Is There a Brain Microbiome? *Neuroscience Insights*, *16*. https://doi.org/10.1177/26331055211018709

Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012). Diversity, stability and resilience

of the human gut microbiota. *Nature*, *489*(7415), 220–230. https://doi.org/10.1038/nature11550

Macpherson, A. J., Hunziker, L., McCoy, K., & Lamarre, A. (2001). IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. *Microbes and Infection*, *3*(12), 1021–1035. https://doi.org/10.1016/S1286-4579(01)01460-5

Maldonado-Contreras, A., Goldfarb, K. C., Godoy-vitorino, F., Karaoz, U., Blaser, M. J., Brodie, E. L., & Dominguez-bello, M. G. (2011). Structure of the human gastric bacterial community in relation to Helicobacter pylori status. *The ISME Journal*, *5*, 574–579. https://doi.org/10.1038/ismej.2010.149

Marchesi, J. R., & Ravel, J. (2015). The vocabulary of microbiome research: a proposal. *Microbiome*, *3*(1), 1–3. https://doi.org/10.1186/s40168-015-0094-5

Marcobal, A., Kashyap, P. C., Nelson, T. A., Aronov, P. A., Donia, M. S., Spormann, A., Fischbach, M. A., & Sonnenburg, J. L. (2013). A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. *ISME Journal*, *7*(10), 1933–1943. https://doi.org/10.1038/ismej.2013.89

Margulis, L. (1967). On the origin of mitosing cells. *Journal of Theoretical Biology*, *14*(3), 255–274. http://www.ncbi.nlm.nih.gov/pubmed/11541390

Margulis, L., & Fester, R. (1991). *Symbiosis as a Source of Evolutionary Innovation*. The MIT Press.

Martinez-Guryn, K., Hubert, N., Frazier, K., Urlass, S., Mark, W., Ojeda, P., Pierre, J. F., Miyoshi, J., Sontag, T., Cham, C., Reardon, C., Leone, V., & Chang, E. B. (2018). Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. *Cell Host and Microbe*, *23*(4), 458–469. https://doi.org/10.1016/j.chom.2018.03.011

Martins-de-Souza, D. (2014). Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. *Dialogues in Clinical Neuroscience*, *16*(1), 63–73. https://doi.org/10.31887/dcns.2014.16.1/dmartins

Mathieu, E., Escribano-Vazquez, U., Descamps, D., Cherbuy, C., Langella, P., Riffault, S., Remot, A., & Thomas, M. (2018). Paradigms of lung microbiota functions in health and disease, particularly, in asthma. *Frontiers in Physiology*, *9*(AUG), 1–11. https://doi.org/10.3389/fphys.2018.01168

Matsumoto, M., Kibe, R., Ooga, T., Aiba, Y., Kurihara, S., Sawaki, E., Koga, Y., & Benno, Y. (2012). Impact of intestinal microbiota on intestinal luminal metabolome. *Scientific Reports*, *2*, 1–10. https://doi.org/10.1038/srep00233

Maynard, C. L., Elson, C. O., Hatton, R. D., & Weaver, C. T. (2012). Reciprocal interactions of the intestinal microbiota and immune system. *Nature*, *489*(7415), 231–241. https://doi.org/10.1038/nature11551

McDonald, D., Hyde, E., Debelius, J. W., Morton, J. T., Gonzalez, A., Ackermann, G., Aksenov, A. A., Behsaz, B., Brennan, C., Chen, Y., DeRight Goldasich, L., Dorrestein, P. C., Dunn, R. R., Fahimipour, A. K., Gaffney, J., Gilbert, J. A., Gogul, G., Green, J. L., Hugenholtz, P., … Goldasich, D. L. (2018). American Gut: an Open Platform for Citizen Science Microbiome Research. *MSystems*, *3*(3), 1–28. http://humanfoodproject.com/

McHardy, I. H., Goudarzi, M., Tong, M., Ruegger, P. M., Schwager, E., Weger, J. R., Graeber, T. G., Sonnenburg, J. L., Horvath, S., Huttenhower, C., Mcgovern, D. P. B., Jr, A. J. F., Borneman, J., & Braun, J. (2013). Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. *Microbiome*, *1*(17), 1–19. https://doi.org/10.1186/2049-2618-1-17

Meng, C., Zeleznik, O. A., Thallinger, G. G., Kuster, B., Gholami, A. M., & Culhane, A. C. (2016). Dimension reduction techniques for the integrative analysis of multi-omics data. *Briefings in Bioinformatics*, *17*(4), 628–641. https://doi.org/10.1093/bib/bbv108

Milani, C., Duranti, S., Bottacini, F., Casey, E., Turroni, F., Mahony, J., Belzer, C., Palacio, D., Rodriguez, J. M., Bode, L., Vos, W. De, & Gueimonde, M. (2017). The First Microbial Colonizers of the Human Gut : Composition , Activities , and Health Implications of the Infant Gut Microbiota. *Microbiology and Molecular Biology Reviews*, *81*(4), 1–67.

Appendix no. 1

Mohajeri, M. H., Brummer, R. J. M., Rastall, R. A., Weersma, R. K., Harmsen, H. J. M., Faas, M., & Eggersdorfer, M. (2018). The role of the microbiome for human health: from basic science to clinical applications. *European Journal of Nutrition*, *57*(1), 1–14. https://doi.org/10.1007/s00394-018-1703-4

Morrison, D. J., & Preston, T. (2016). Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes*, *7*(3), 189–200. https://doi.org/10.1080/19490976.2015.1134082

Morton, E. R., Lynch, J., Froment, A., Lafosse, S., Heyer, E., Przeworski, M., Blekhman, R., & Ségurel, L. (2015). Variation in Rural African Gut Microbiota Is Strongly Correlated with Colonization by Entamoeba and Subsistence. *PLoS Genetics*, *11*(11), 1–28. https://doi.org/10.1371/journal.pgen.1005658

Muegge, B. D., Kuczynski, J., Knights, D., Clemente, J. C., González, A., Fontana, L., Henrissat, B., Knight, R., & Gordon, J. I. (2011). Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. *Science*, *332*(6032), 970–974. https://doi.org/10.1126/science.1198719

Najmanová, L., Vídeňská, P., & Cahová, M. (2022). Healthy Microbiome – A Mere Idea or a Sound Concept? *Physiological Research*, *71*(6), 719–738. https://doi.org/10.33549/physiolres.934967

Neefs, J., Peer, Y. Van De, Rijk, P. De, Chapelle, S., Wachter, R. De, Biochemie, D., Uia, U. A., & Antwerp, B.-. (1993). Compilation of small ribosomal subunit RNA structures. *Nucleic Acids Research*, *21*(13), 3025–3049. https://doi.org/10.1093/nar/21.13.3025

Neugent, M. L., Hulyalkar, N. V., Nguyen, V. H., Zimmern, P. E., & De Nisco, N. J. (2020). Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. *MBio*, *11*(2), 1–15. https://doi.org/10.1128/mBio.00218-20

Nikolov, M., Schmidt, C., & Urlaub, H. (2021). Quantitative mass spectrometry-based proteomics: An overview. In *Quantitative Methods in Proteomics* (Vol. 2228, pp. 85–100). https://doi.org/10.1007/978-1-61779-885-6_7

Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health. *Microbiome*, *7*(1), 1–15. https://doi.org/10.1186/s40168-019-0704-8

Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D., & Cox, L. A. (2019). The need for multi-omics biomarker signatures in precision medicine. *International Journal of Molecular Sciences*, *20*(19). https://doi.org/10.3390/ijms20194781

Ottman, N., Smidt, H., de Vos, W. M., & Belzer, C. (2012). The function of our microbiota: who is out there and what do they do? *Frontiers in Cellular and Infection Microbiology*, *2*(August), 104. https://doi.org/10.3389/fcimb.2012.00104

Ouwerkerk, J. P., De Vos, W. M., & Belzer, C. (2013). Glycobiome: Bacteria and mucus at the epithelial interface. *Best Practice and Research: Clinical Gastroenterology*, *27*(1), 25–38. https://doi.org/10.1016/j.bpg.2013.03.001

Paone, P., & Cani, P. D. (2020). Mucus barrier, mucins and gut microbiota: The expected slimy partners? *Gut*, *69*(12), 2232–2243. https://doi.org/10.1136/gutjnl-2020-322260

Park, M., Kim, D., Moon, K., & Park, T. (2020). Integrative analysis of multi-omics data based on blockwise sparse principal components. *International Journal of Molecular Sciences*, *21*(21), 1–17. https://doi.org/10.3390/ijms21218202

Parks, D. H., Chuvochina, M., Waite, D. W., Rinke, C., Skarshewski, A., Chaumeil, P. A., & Hugenholtz, P. (2018). A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life. *Nature Biotechnology*, *36*(10), 996. https://doi.org/10.1038/nbt.4229

Pasolli, E., Asnicar, F., Manara, S., Zolfo, M., Karcher, N., Armanini, F., Beghini, F., Manghi, P., Tett, A., Ghensi, P., Collado, M. C., Rice, B. L., DuLong, C., Morgan, X. C., Golden, C. D., Quince, C., Huttenhower, C., & Segata, N. (2019). Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell*, *176*(3), 649-662.e20. https://doi.org/10.1016/j.cell.2019.01.001

Appendix no. 1

Patangia, D. V, Ryan, C. A., Dempsey, E., & Stanton, C. (2022). *Impact of antibiotics on the human microbiome and consequences for host health*. *September 2021*, 1–23. https://doi.org/10.1002/mbo3.1260

Peck, B. C. E., Mah, A. T., Pitman, W. A., Ding, S., Lund, P. K., & Sethupathy, P. (2017). Functional transcriptomics in diverse intestinal epithelial cell types reveals robust MicroRNA sensitivity in intestinal stem cells to microbial status. *Journal of Biological Chemistry*, *292*(7), 2586–2600. https://doi.org/10.1074/jbc.M116.770099

Picard, M., Scott-Boyer, M. P., Bodein, A., Périn, O., & Droit, A. (2021). Integration strategies of multi-omics data for machine learning analysis. *Computational and Structural Biotechnology Journal*, *19*, 3735–3746. https://doi.org/10.1016/j.csbj.2021.06.030

Piovesan, A., Pelleri, M. C., Antonaros, F., Strippoli, P., Caracausi, M., & Vitale, L. (2019). On the length , weight and GC content of the human genome. *BMC Research Notes*, *12*(106), 1–7. https://doi.org/10.1186/s13104-019-4137-z

Potgieter, M., Bester, J., Kell, D. B., & Pretorius, E. (2015). *The dormant blood microbiome in chronic , inflammatory diseases*. *March*, 567–591. https://doi.org/10.1093/femsre/fuv013

Prochazkova, M., Budinska, E., Kuzma, M., Pelantova, H., Hradecky, J., Heczkova, M., Daskova, N., Bratova, M., Modos, I., Videnska, P., Splichalova, P., Sowah, S. A., Kralova, M., Henikova, M., Selinger, E., Klima, K., Chalupsky, K., Sedlacek, R., Landberg, R., … Cahova, M. (2022). Vegan Diet Is Associated With Favorable Effects on the Metabolic Performance of Intestinal Microbiota: A Cross-Sectional Multi-Omics Study. *Frontiers in Nutrition*, *8*(January), 1–18. https://doi.org/10.3389/fnut.2021.783302

Prodan, A., Tremaroli, V., Brolin, H., Zwinderman, A. H., Nieuwdorp, M., & Levin, E. (2020). Comparing bioinformatic pipelines for microbial 16S rRNA amplicon sequencing. *PLoS ONE*, *15*(1), 1–19. https://doi.org/10.1371/journal.pone.0227434

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., … Zoetendal, E. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*, *464*(7285), 59–65. https://doi.org/10.1038/nature08821

Quince, C., Walker, A. W., Simpson, J. T., Loman, N. J., & Segata, N. (2017). Shotgun metagenomics, from sampling to analysis. *Nature Biotechnology*, *35*(9), 833–844. https://doi.org/10.1038/nbt.3935

Quinn, R. A., Melnik, A. V., Vrbanac, A., Fu, T., Patras, K. A., Christy, M. P., Bodai, Z., Belda-Ferre, P., Tripathi, A., Chung, L. K., Downes, M., Welch, R. D., Quinn, M., Humphrey, G., Panitchpakdi, M., Weldon, K. C., Aksenov, A., da Silva, R., Avila-Pacheco, J., … Dorrestein, P. C. (2020). Global chemical effects of the microbiome include new bile-acid conjugations. *Nature*, *579*(7797), 123–129. https://doi.org/10.1038/s41586-020-2047-9

Reel, P. S., Reel, S., Pearson, E., Trucco, E., & Jefferson, E. (2021). Using machine learning approaches for multi-omics data analysis: A review. *Biotechnology Advances*, *49*(March), 107739. https://doi.org/10.1016/j.biotechadv.2021.107739

Rew, L., Harris, M. D., & Goldie, J. (2022). The ketogenic diet : its impact on human gut microbiota and potential consequent health outcomes : a systematic literature review. *Gastroenterol Hepatol Bed*, *15*(4), 326–342. https://doi.org/10.22037/ghfbb.v15i4.2600

Reynoso-García, J., Miranda-Santiago, A. E., Meléndez-Vázquez, N. M., Acosta-Pagán, K., Sánchez-Rosado, M., Díaz-Rivera, J., Rosado-Quiñones, A. M., Acevedo-Márquez, L., Cruz-Roldán, L., Tosado-Rodríguez, E. L., Figueroa-Gispert, M. D. M., & Godoy-Vitorino, F. (2022). A complete guide to human microbiomes: Body niches, transmission, development, dysbiosis, and restoration. *Frontiers in Systems Biology*, *2*(951403), 1–22. https://doi.org/10.3389/fsysb.2022.951403

Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D. J., & Hylemon, P. B. (2016). Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes*, *7*(1), 22–39. https://doi.org/10.1080/19490976.2015.1127483

Ridlon, J. M., Kang, D. J., & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. *Journal*

of Lipid Research, *47*(2), 241–259. https://doi.org/10.1194/jlr.R500013-JLR200

Rodosthenous, T., Shahrezaei, V., & Evangelou, M. (2020). Integrating multi-OMICS data through sparse canonical correlation analysis for the prediction of complex traits: A comparison study. *Bioinformatics*, *36*(17), 4616–4625. https://doi.org/10.1093/bioinformatics/btaa530

Rosenbaum, M., Knight, R., & Leibel, R. L. (2015). The gut microbiota in human energy homeostasis and obesity. *Trends Endocrinol Metab.*, *26*(9), 493–501. https://doi.org/10.1016/j.tem.2015.07.002

Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P. I., Godneva, A., Kalka, I. N., Bar, N., Shilo, S., Lador, D., Vila, A. V., Zmora, N., Pevsner-Fischer, M., Israeli, D., Kosower, N., Malka, G., Wolf, B. C., … Segal, E. (2018). Environment dominates over host genetics in shaping human gut microbiota. *Nature*, *555*(7695), 210–215. https://doi.org/10.1038/nature25973

Salazar, N., Gonzalez, S., NIgacka, A., Rios-covián, D., Arboleya, S., Gueimonde, M., & de Los Reyes-Gavilán, C. G. (2019). Microbiome: Effects of Ageing and Diets. In *Microbiota: current research and emerging trends* (Vol. 7). https://doi.org/10.21775/9781910190937.01

Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H. U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013). Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metabolism*, *17*(2), 225–235. https://doi.org/10.1016/j.cmet.2013.01.003

Schnorr, S. L., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G., Turroni, S., Biagi, E., Peano, C., Severgnini, M., Fiori, J., Gotti, R., De Bellis, G., Luiselli, D., Brigidi, P., Mabulla, A., Marlowe, F., Henry, A. G., & Crittenden, A. N. (2014). Gut microbiome of the Hadza hunter-gatherers. *Nature Communications*, *5*. https://doi.org/10.1038/ncomms4654

Schoenborn, A. A., von Furstenberg, R. J., Valsaraj, S., Hussain, F. S., Stein, M., Shanahan, M. T., Henning, S. J., & Gulati, A. S. (2019). The enteric microbiota regulates jejunal Paneth cell number and function without impacting intestinal stem cells. *Gut Microbes*, *10*(1), 45–58. https://doi.org/10.1080/19490976.2018.1474321

Schroeder, B. O., & Bäckhed, F. (2016). Signals from the gut microbiota to distant organs in physiology and disease. *Nature Medicine*, *22*(10), 1079–1089. https://doi.org/10.1038/nm.4185

Sender, R., Fuchs, S., & Milo, R. (2016a). Are We Really Vastly Outnumbered ? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell*, *164*(3), 337–340. https://doi.org/10.1016/j.cell.2016.01.013

Sender, R., Fuchs, S., & Milo, R. (2016b). Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biology*, *14*(8), 1–21. https://doi.org/10.1371/journal.pbio.1002533

Sharma, R., Schumacher, U., Ronaasen, V., & Coates, M. (1995). Rat intestinal mucosal responses to a microbial flora and different diets. *Gut*, *36*(2), 209–214. https://doi.org/10.1136/gut.36.2.209

Sharon, I., Mart, N., Pasolli, E., Fabbrini, M., Vitali, F., Agamennone, V., Dötsch, A., Selberherr, E., Grau, H., Meixner, M., Liere, K., Ercolini, D., Filippo, C. De, Caderni, G., Brigidi, P., & Turroni, S. (2022). *The Core Human Microbiome : Does It Exist and How Can We Find It ? A Critical Review of the Concept*. 1–25.

Shendure, J., Findlay M., G., & Snyder W., M. (2019). Genomic medicine - progress, pitfalls, and promise. *Cell*, *177*(1), 45–57. https://doi.org/10.1016/j.cell.2019.02.003

Simon, J. C., Marchesi, J. R., Mougel, C., & Selosse, M. A. (2019). Host-microbiota interactions: From holobiont theory to analysis. *Microbiome*, *7*(1), 1–5. https://doi.org/10.1186/s40168-019-0619-4

Singh, R. K., Chang, H. W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T. H., Bhutani, T., & Liao, W. (2017). Influence of diet on the gut microbiome and implications for human health. *Journal of Translational Medicine*, *15*(1), 1–17. https://doi.org/10.1186/s12967-017-1175-y

Slatko, B., Gardner, A. F., & Ausubel, F. M. (2018). Overview of Next Generation Sequencing Technologies. *Curr Protoc Mol Biol.*, *122*(1), 1–15. https://doi.org/10.1002/cpmb.59

Smits, S. A., Leach, J., Sonnenburg, E. D., Gonzalez, C. G., Lichtman, J. S., Reid, G., Knight, R., Manjurano, A., Changalucha, J., Elias, J. E., Dominguez-Bello, M. G., & Sonnenburg, J. L. (2017). Seasonal Cycling in the Gut Microbiome of the Hadza Hunter- Gatherers of Tanzania. *Science*, *357*(6563), 802–806. https://doi.org/10.1126/science.aan4834.Seasonal

Sommer, F., & Bäckhed, F. (2013). The gut microbiota-masters of host development and physiology. *Nature Reviews Microbiology*, *11*(4), 227–238. https://doi.org/10.1038/nrmicro2974

Sonnenburg, J. L., & Bäckhed, F. (2014). Diet – microbiota interactions as moderators of human metabolism. *Nature*, *535*, 56–64. https://doi.org/10.1038/nature18846

Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017). Interaction of Gut Microbiota with Bile Acid Metabolism and its Influence on Disease States. *Appl Microbiol Biotechnol.*, *101*(1), 47–64. https://doi.org/10.1007/s00253-016-8006-6

Stewart, C. J., Ajami, N. J., O'Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., Ross, M. C., Lloyd, R. E., Doddapaneni, H. V., Metcalf, G. A., Muzny, D., Gibbs, R. A., Vatanen, T., Huttenhower, C., Xavier, R. J., Rewers, M., Hagopian, W., Toppari, J., Ziegler, A. G., … Petrosino, J. F. (2018). Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature*, *562*(7728), 583–588. https://doi.org/10.1038/s41586-018-0617-x

Suhre, K., McCarthy, M. I., & Schwenk, J. M. (2021). Genetics meets proteomics: perspectives for large population-based studies. *Nature Reviews Genetics*, *22*(1), 19–37. https://doi.org/10.1038/s41576-020-0268-2

Swaney, M. H. (2021). *Living in Your Skin : Microbes , Molecules , and Mechanisms*. January.

Swann, J. R., Want, E. J., Geier, F. M., Spagou, K., Wilson, I. D., Sidaway, J. E., Nicholson, J. K., & Holmes, E. (2011). Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. *Proceedings of the National Academy of Sciences of the United States of America*, *108*(SUPPL. 1), 4523–4530. https://doi.org/10.1073/pnas.1006734107

Tebani, A., Afonso, C., Marret, S., & Bekri, S. (2016). Omics-based strategies in precision medicine: Toward a paradigm shift in inborn errors of metabolism investigations. *International Journal of Molecular Sciences*, *17*(9). https://doi.org/10.3390/ijms17091555

The Human Microbiome Project Consortium. (2012). Structure , function and diversity of the healthy human microbiome. *Nature*, *486*(7402), 207–214. https://doi.org/10.1038/nature11234

Tian, L., Wang, X. W., Wu, A. K., Fan, Y., Friedman, J., Dahlin, A., Waldor, M. K., Weinstock, G. M., Weiss, S. T., & Liu, Y. Y. (2020). Deciphering functional redundancy in the human microbiome. *Nature Communications*, *11*(1), 1–11. https://doi.org/10.1038/s41467-020-19940-1

Tibshirani, R. (1996). Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society*, *58*(1), 267–288.

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. a, Jason, P., Egholm, M., Henrissat, B., Heath, A. C., Knight, R., Gordon, J. I., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., … Gordon, J. I. (2009). A core gut microbiome between lean and obesity twins. *Nature*, *457*(7228), 480–484. https://doi.org/10.1038/nature07540.A

Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007). The Human Microbiome Project. *Nature*, *449*(7164), 804–810. https://doi.org/10.1038/nature06244

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*, *444*(7122), 1027–1031. https://doi.org/10.1038/nature05414

Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009). The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice. *Sci Transl Med.*, *1*(6), 1–19. https://doi.org/10.1126/scitranslmed.3000322

Tyakht, A. V, Kostryukova, E. S., Popenko, A. S., Belenikin, M. S., Pavlenko, A. V, Larin, A. K., Karpova, I. Y.,

Appendix no. 1

Selezneva, O. V, Semashko, T. A., Ospanova, E. A., Babenko, V. V, Maev, I. V, Cheremushkin, S. V, Kucheryavyy, Y. A., Shcherbakov, P. L., Grinevich, V. B., Efimov, O. I., Sas, E. I., Abdulkhakov, R. A., … Alexeev, D. G. (2013). Human gut microbiota community structures in urban and rural populations in Russia. *Nature Communications*, *4*(2469), 1–9. https://doi.org/10.1038/ncomms3469

Ursell, L. K., Metcalf, J. L., Parfrey Wegener, L., & Knight, R. (2012). Defining the Human Microbiome. *Nutr Rev.*, *70*(August), 38–44. https://doi.org/10.1111/j.1753-4887.2012.00493.x

Vandenplas, Y., Carnielli, V. P., Ksiazyk, J., Luna, M. S., Migacheva, N., Mosselmans, J. M., Picaud, J. C., Possner, M., Singhal, A., & Wabitsch, M. (2020). Factors affecting early-life intestinal microbiota development. *Nutrition*, *78*, 110812. https://doi.org/10.1016/j.nut.2020.110812

Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., Lernmark, Å., Hagopian, W. A., Rewers, M. J., She, J. X., Toppari, J., Ziegler, A. G., Akolkar, B., Krischer, J. P., Stewart, C. J., Ajami, N. J., Petrosino, J. F., Gevers, D., Lähdesmäki, H., … Xavier, R. J. (2018). The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*, *562*(7728), 589–594. https://doi.org/10.1038/s41586-018-0620-2

Venegas, D. P., De La Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019). Short chain fatty acids (SCFAs)mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Frontiers in Immunology*, *10*(MAR). https://doi.org/10.3389/fimmu.2019.00277

Vujkovic-Cvijin, I., Sklar, J., Jiang, L., Natarajan, L., Knight, R., Belkaid, Y., Section, I., Diseases, I., Diseases, I., Program, M., Jolla, L., Jolla, L., Jolla, L., Jolla, L., & Jolla, L. (2020). Host variables confound gut microbiota studies of human disease. *Nature*, *587*(7834), 448–454. https://doi.org/10.1038/s41586-020-2881-9

Wahlström, A., Sayin, S. I., Marschall, H. U., & Bäckhed, F. (2016). Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metabolism*, *24*(1), 41–50. https://doi.org/10.1016/j.cmet.2016.05.005

Wang, Z., Gerstein, M., & Snyder, M. (2009). RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet.*, *10*(1), 57–63. https://doi.org/10.1038/nrg2484.RNA-Seq

Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., Robinson, J. L., Elias, J. E., Sonnenburg, E. D., Gardner, C. D., & Sonnenburg, J. L. (2021). Gut-microbiota-targeted diets modulate human immune status. *Cell*, *184*(16), 4137-4153.e14. https://doi.org/10.1016/j.cell.2021.06.019

Whiteside, S. A., McGinniss, J. E., & Collman, R. G. (2021). The lung microbiome: Progress and promise. *Journal of Clinical Investigation*, *131*(15), 1–10. https://doi.org/10.1172/JCI150473

Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proceedings of the National Academy of Sciences of the United States of America*, *106*(10), 3698–3703. https://doi.org/10.1073/pnas.0812874106

Woese, C. R., & Fox, G. E. (1977). *Phylogenetic structure of the prokaryotic domain : The primary kingdoms*. *74*(11), 5088–5090.

Woese, C. R., Kandlert, O., & Wheelis, M. L. (1990). *Towards a natural system of organisms : Proposal for the domains*. *87*(June), 4576–4579.

Wolfe, A. J., Toh, E., Shibata, N., Rong, R., Kenton, K., Fitzgerald, M., Mueller, E. R., Schreckenberger, P., Dong, Q., Nelson, D. E., & Brubaker, L. (2012). *Evidence of Uncultivated Bacteria in the Adult Female Bladder*. 1376–1383. https://doi.org/10.1128/JCM.05852-11

Wu, C., Zhou, F., Ren, J., Li, X., Jiang, Y., & Ma, S. (2019). A selective review of multi-level omics data integration using variable selection. *High-Throughput*, *8*(1), 1–25. https://doi.org/10.3390/ht8010004

Wu, S., Hugerth, L. W., & Schuppe-koistinen, I. (2022). The right bug in the right place : opportunities for bacterial vaginosis treatment. *NPJ Biofilms Microbiomes*, *8*(1), 1–11. https://doi.org/10.1038/s41522-022-00295-y

Appendix no. 1

Xue, Z., Kable, M. E., & Marco, M. L. (2018). Impact of DNA Sequencing and Analysis Methods on 16S rRNA Gene Bacterial Community Analysis of Dairy Products. *MSphere*, *3*(5), 1–14. https://doi.org/10.1128/msphere.00410-18

Yagi, K., Huffnagle, G. B., Lukacs, N. W., & Asai, N. (2021). The lung microbiome during health and disease. *International Journal of Molecular Sciences*, *22*(19), 1–13. https://doi.org/10.3390/ijms221910872

Yatsunenko, T., Rey, F. E., Manary, M. J., & Trehan, I. (2012). Human gut microbiome viewed across age and geography Tanya. *Nature*, *486*(7402), 222–227. https://doi.org/10.1038/nature11053.Human

Ye, L., & Rawls, J. F. (2021). Microbial influences on gut development and gut-brain communication. *Development (Cambridge)*, *148*(21). https://doi.org/10.1242/dev.194936

Yu, Y., Raka, F., & Adeli, K. (2019). The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. *Journal of Clinical Medicine*, *8*(12), 2227. https://doi.org/10.3390/jcm8122227

Zierer, J., Jackson, M. A., Kastenmüller, G., Mangino, M., Long, T., Telenti, A., Mohney, R. P., Small, K. S., Bell, J. T., Steves, C. J., Valdes, A. M., Spector, T. D., & Menni, C. (2018). The fecal metabolome as a functional readout of the gut microbiome. *Nature Genetics*, *50*(6), 790–795. https://doi.org/10.1038/s41588-018-0135-7

Zimmermann, M., Zimmermann-kogadeeva, M., & Wegmann, R. (2019). Mapping human microbiome drug metabolism by gut bacteria and their genes. *Nature*, *570*(7762), 462–467. https://doi.org/10.1038/s41586-019-1291-3

Zoetendal, E. G., Raes, J., Van Den Bogert, B., Arumugam, M., Booijink, C. C., Troost, F. J., Bork, P., Wels, M., De Vos, W. M., & Kleerebezem, M. (2012). The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. *ISME Journal*, *6*(7), 1415–1426. https://doi.org/10.1038/ismej.2011.212

8 LIST OF AUTHOR'S PUBLICATIONS

Publications with a direct relation to the thesis

Daskova N., Modos I., Krbcova M., Kuzma M., Pelantova H., Hradecky J., Heczkova M., *et al.* 2023. "Multi-omics signatures in new-onset diabetes predict metabolic response to dietary inulin: findings from an observational study followed by an interventional trial." Nutrition & Diabetes 13 (1): 1–13. https://doi.org/10.1038/s41387-023-00235-5. **IF (2023) = 4.73**

Daskova N., Heczkova M., Modos I., Hradecky J., Hudcovic T., Kuzma M., Pelantova H., *et al.* 2023. "Protective Effect of Vegan Microbiota on Liver Steatosis Is Conveyed by Dietary Fiber: Implications for Fecal Microbiota Transfer Therapy." Nutrients 15 (454): 1–18. https://doi.org/10.3390/nu15020454. **IF (2023) = 5.43**

Prochazkova M., Budinska E., Kuzma M., Pelantova H., Hradecky J., Heczkova M., Daskova N., *et al*. 2022. "Vegan Diet is Associated with Favorable Effects on the Metabolic Performance of Intestinal Microbiota: A Cross-Sectional Multi-Omics Study." Frontiers in Nutrition 8 (January): 1–18. https://doi.org/10.3389/fnut.2021.783302. **IF (2022) = 6.59**

Daskova N., Heczkova M., Modos I., Videnska P., Splichalova P., Pelantova H., Kuzma M., Gojda J. and Cahova M. 2021. "Determination of Butyrate Synthesis Capacity in Gut Microbiota: Quantification of but Gene Abundance by Qpcr in Fecal Samples." Biomolecules 11 (9). https://doi.org/10.3390/biom11091303. **IF (2021) = 5.88**

Publications with no relation to the thesis

Fabian O., Bajer L., Drastich P., Harant K., Sticova E., Daskova N., Modos I., *et al*. 2023. "A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review." International Journal of Molecular Sciences 24 (11): 1–28. https://doi.org/10.3390/ijms24119386. **IF (2023) = 6.21**

Kosek V., Heczkova M., Novak F., Meisnerova E., Novakova O., Zelenka J., Bechynska K., *et al*. 2020. "The ω-3 Polyunsaturated Fatty Acids and Oxidative Stress in Long-Term Parenteral Nutrition Dependent Adult Patients: Functional Lipidomics Approach." Nutrients 12 (8): 1–15. https://doi.org/10.3390/nu12082351. **IF (2020) = 5.72**

Bechynska K., Daskova N., Vrzackova N., Harant K., Heczkova M., Podzimkova K., Bratova M., *et al*. 2019. "The Effect of ω-3 Polyunsaturated Fatty Acids on the Liver Lipidome, Proteome and Bile Acid Profile: Parenteral versus Enteral Administration." Scientific Reports 9 (1): 1–14. https://doi.org/10.1038/s41598-019-54225-8. **IF (2019) = 4.16**

Seda O., Cahova M., Mikova I., Sedova L., Dankova H., Heczkova M., Bratova M., *et al*. 2019. "Hepatic Gene Expression Profiles Differentiate Steatotic and Non-Steatotic Grafts in Liver Transplant Recipients." Frontiers in Endocrinology 10 (April). https://doi.org/10.3389/fendo.2019.00270. **IF (2019) = 3.64**

Cahova M., Dankova H., Heczkova M., Bratova M., Daskova N., Bastova H., Gojda J. and Wohl P. 2019. "MicroRNAs as Potential Markers of Parenteral Nutrition-Associated Liver Disease in Adult Patients." Physiological Research 68 (4): 681–88. https://doi.org/10.33549/physiolres.934103. **IF (2019) = 1.66**